Vetter Pharma
Vetter Pharma, officially known as Vetter Pharma-Fertigung GmbH & Co. KG, is a leading global provider of aseptic filling and packaging services for the pharmaceutical and biotechnology industries. Headquartered in Ravensburg, Germany, the company operates extensively across Europe, North America, and Asia, catering to a diverse clientele. Founded in 1950, Vetter Pharma has achieved significant milestones, including the development of innovative delivery systems and a commitment to high-quality standards. The company specialises in prefilled syringes, vials, and cartridges, distinguished by their precision and reliability. Vetter's strong market position is underscored by its reputation for excellence and a robust portfolio of services that support drug development and commercialisation. With a focus on customer-centric solutions, Vetter Pharma continues to be a trusted partner in the evolving landscape of healthcare.
DitchCarbon Score
How does Vetter Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vetter Pharma's score of 39 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vetter Pharma's reported carbon emissions
In 2024, Vetter Pharma reported total carbon emissions of approximately 16,986,000 kg CO2e, with Scope 1 emissions accounting for about 16,986,000 kg CO2e and Scope 3 emissions at approximately 3,778,000 kg CO2e. The Scope 1 emissions primarily stem from stationary combustion, which contributed about 16,044,200 kg CO2e. Vetter Pharma has set ambitious climate commitments, aiming for a significant reduction in emissions. The company targets a 58.8% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2021 as the base year. This target is currently being validated by the Science Based Targets initiative (SBTi). Additionally, Vetter Pharma is committed to ensuring that 80% of its suppliers, by spend, will have science-based targets by 2029. The company also has a long-term goal of achieving net zero emissions by 2050, which reflects its commitment to balancing emissions to reach zero. These initiatives position Vetter Pharma as a proactive player in the pharmaceutical sector's response to climate change, aligning with global efforts to mitigate greenhouse gas emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 19,683,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vetter Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
